Micro RNA-4651 Serves as a Potential Biomarker for Prognosis When Selecting Hepatocellular Carcinoma Patients for Postoperative Adjuvant Transarterial Chemoembolization Therapy.
Micro RNA-4651 Serves as a Potential Biomarker for Prognosis When Selecting Hepatocellular Carcinoma Patients for Postoperative Adjuvant Transarterial Chemoembolization Therapy.
复制标题
在选择肝细胞癌患者进行术后辅助经动脉化疗栓塞治疗时，Micro RNA-4651 可作为预后的潜在生物标志物
DOI：
10.1002/hep4.1245
复制
发表时间：
2018-10
影响因子：
5.1
通讯作者：
Ma Y
中科院分区：
文献类型：
--
作者：
Zhang TQ;Su QQ;Huang XY;Yao JG;Wang C;Xia Q;Long XD;Ma Y
我们之前的报告表明，microRNA-4651是肝细胞癌的潜在早期诊断和预后标志物。我们的目的是研究microRNA-4651是否修饰术后辅助经动脉化疗栓塞（pa-TACE）以改善肝癌的预后。进行了一项基于医院的回顾性研究，包括302例接受肿瘤切除术或肿瘤切除术+pa‐TACE作为初始治疗的晚期肝细胞癌患者，以评估microRNA‐4651对pa‐TACE治疗的影响。使用TaqMan-PCR技术测试肿瘤组织中的MicroRNA-4651表达。通过半数最大抑制浓度（IC 50）分析肿瘤细胞对多柔比星（pa-TACE手术中使用的抗癌药物）的敏感性。肿瘤组织中microRNA-4651表达上调可改善肝细胞癌患者对pa-TACE的治疗反应（死亡风险的风险比[95%置信区间] = 0.32 [0.22 - 0.46]，肿瘤复发风险的风险比[95%置信区间] = 0.39 [0.28 - 0.56]），但表达下调不能。功能分析显示，microRNA-4651模拟物减少，而其抑制剂增加了肿瘤细胞对阿霉素的IC 50（0.65 [0.61 - 0.69] vs 2.17 [1.98 - 2.37] µM）。细胞色素P450 2 W1被证明是microRNA-4651的可能靶点。此外，microRNA-4651的失调也影响肝细胞癌的临床病理特征，并且是这种癌症的独立预后因素。结论：这些结果表明，增加microRNA-4651表达可能有利于pa-TACE改善肝细胞癌预后。
Our previous reports have shown that microRNA‐4651 is a potential early diagnostic and prognostic marker for hepatocellular carcinoma. We aimed to investigate whether microRNA‐4651 modified postoperative adjuvant transarterial chemoembolization (pa‐TACE) to improve the prognosis of hepatocellular carcinoma. A hospital‐based retrospective study, including 302 patients with advanced‐stage hepatocellular carcinoma who received tumor resection or tumor resection plus pa‐TACE as an initial therapy, was conducted to assess the effects of microRNA‐4651 on pa‐TACE treatment. MicroRNA‐4651 expression in tumor tissues was tested using the TaqMan‐PCR technique. The sensitivity of tumor cells to doxorubicin (an anticancer drug used in pa‐TACE procedure) was analyzed by the half‐maximal inhibitory concentration (IC50). Upregulated microRNA‐4651 expression in tumor tissues can improve the therapeutic response of patients with hepatocellular carcinoma on pa‐TACE (hazard ratios [95% confidence intervals] = 0.32 [0.22‐0.46] for death risk and 0.39 [0.28‐0.56] for tumor‐recurrence risk, respectively), but downregulated expression cannot. Functional analyses–displayed microRNA‐4651 mimics decreased while its inhibitor increased the IC50 of tumor cells to doxorubicin (0.65 [0.61‐0.69] versus 2.17 [1.98‐2.37] µM). Cytochrome P450 2W1 was shown as a possible target of microRNA‐4651. Additionally, dysregulation of microRNA‐4651 also affected the clinical pathological features of hepatocellular carcinoma and was an independent prognostic factor for this cancer. Conclusion: These results indicate that increasing microRNA‐4651 expression may be beneficial for pa‐TACE in improving hepatocellular carcinoma prognosis.
登录
查看更多内容
MicroRNA-24 调节黄曲霉毒素 B1 相关的肝细胞癌预后和肿瘤发生
影响因子：
--
作者：
Liu YX;Long XD;Xi ZF;Ma Y;Huang XY;Yao JG;Wang C;Xing TY;Xia Q
通讯作者：
Xia Q
影响因子：
3.8
作者：
Huang, Xiao-Ying;Yao, Jin-Guang;Long, Xi-Dai
通讯作者：
Long, Xi-Dai
XRCC4表达在肝细胞癌中的预后意义
影响因子：
--
作者：
Lu J;Wang XZ;Zhang TQ;Huang XY;Yao JG;Wang C;Wei ZH;Ma Y;Wu XM;Luo CY;Xia Q;Long XD
通讯作者：
Long XD
影响因子：
4
作者：
Bai T;Chen J;Xie ZB;Wu FX;Wang SD;Liu JJ;Li LQ
通讯作者：
Li LQ
miR-1268a表达的预后意义及其对肝细胞癌术后辅助经动脉化疗栓塞的有益作用
影响因子：
4.6
作者：
Lu YL;Yao JG;Huang XY;Wang C;Wu XM;Xia Q;Long XD
通讯作者：
Long XD